Retatrutide Dosage Protocols Revised for 2026

Updated clinical guidance has been issued for Retatrutide, an emerging GLP-1 receptor agonist for weight and metabolic management. The revised protocols focus on balancing efficacy with patient tolerability, recommending a gradual dose increase. Emphasis is placed on monitoring for side effects, individualizing dosages, and integrating lifestyle changes with the therapy.